摘要
左西孟旦是近年来新研制的正性肌力药物,具有独特的双重作用模式,增强心肌收缩力,扩张血管,增加心排血量,同时不增加心肌耗氧,不良反应少,多项临床研究结果均证实,左西孟旦可明显改善失代偿性心力衰竭患者的临床症状,稳定血流动力学指标,明显降低病死率,但对于远期预后,目前研究得出的结论并不一致。
Levosimendan is a newly developed positive inotropic drug.It has an unique dual function pattern,which can strengthen myocardium contractile force,expand the vasoconstrictor,and increase cardiac output without increasing myocardial oxygen.Several studies have confirmed that levosimendan could improve clinical symptoms in patients with decompensated heart failure and significantly reduce mortality.However,there are differing results regarding the long-term prognosis for patients with heart failure.
出处
《心血管病学进展》
CAS
2013年第4期523-525,共3页
Advances in Cardiovascular Diseases
基金
国家自然科学基金青年项目资助(81200189)
关键词
左西孟旦
正性肌力药物
心力衰竭
levosimendan
positive inotropic drug
heart failure
